Although there are currently 30 million chronic headache patients in Japan, the diagnosis and treatment rate of migraine among non-headache specialists is less than 20%. Under these circumstances, there is an urgent need to develop tools to support the diagnosis of headache. The study is expected to validate how the AI can support a broad range of doctors in diagnosing patients, and each of their attacks, in order to select treatments as well as to potentially identify the symptom patterns associated with fatal conditions earlier.

This study will lead to a breakthrough in opening the path to precision medicine and diagnosing the condition of migraine, which affects more than 36 million people in the US alone, and hundreds of millions more worldwide. In the future, it will also enable doctors to better diagnose patients with migraine and other related conditions, as well as allow them to select treatments based on accurate diagnosis. The study has been conducted in 2023 and the results are expected to be published soon after completion.

The AI used in this study is powered by Healint's proprietary technology, an end-to-end machine learning platform for medical and healthcare applications. Healint's platform is called Migraine Buddy, and is the world's most used headache tracking application. The platform uses artificial intelligence to detect patterns from large datasets of patients' data. Over the past 10 years, Migraine Buddy has gained more than 3.5 million users worldwide, has trained AI with their detailed headache and migraine attack records, and has accumulated a large dataset to date from which it is possible to detect patterns.